Shapiro J, Corrado M, Perry J, Watts T, Bolotin S
Hum Vaccin Immunother. 2024; 20(1):2395679.
PMID: 39205626
PMC: 11364080.
DOI: 10.1080/21645515.2024.2395679.
Matucci-Cerinic C, Herzum A, Ciccarese G, Rosina S, Caorsi R, Gattorno M
Open Forum Infect Dis. 2024; 11(7):ofae369.
PMID: 39035570
PMC: 11259138.
DOI: 10.1093/ofid/ofae369.
Herzum A, Ciccarese G, Occella C, Gariazzo L, Pastorino C, Trave I
J Clin Med. 2023; 12(13).
PMID: 37445264
PMC: 10342328.
DOI: 10.3390/jcm12134230.
Zeng Y, Moscicki A, Woo H, Hsu C, Kemp T, Pinto L
Pediatrics. 2023; 152(1).
PMID: 37317810
PMC: 10312231.
DOI: 10.1542/peds.2022-060301.
Prabhu P, Carter J, Galloway D
Vaccines (Basel). 2022; 10(6).
PMID: 35746445
PMC: 9229470.
DOI: 10.3390/vaccines10060837.
Effects of the age of vaccination on the humoral responses to a human papillomavirus vaccine.
Nicoli F, Mantelli B, Gallerani E, Telatin V, Squarzon L, Masiero S
NPJ Vaccines. 2022; 7(1):37.
PMID: 35292655
PMC: 8924199.
DOI: 10.1038/s41541-022-00458-0.
Review of long-term immunogenicity following HPV vaccination: Gaps in current knowledge.
Hoes J, Pasmans H, Klooster T, van der Klis F, Donken R, Berkhof J
Hum Vaccin Immunother. 2021; 18(1):1908059.
PMID: 34033518
PMC: 8920133.
DOI: 10.1080/21645515.2021.1908059.
ABCC6, Pyrophosphate and Ectopic Calcification: Therapeutic Solutions.
Shimada B, Pomozi V, Zoll J, Kuo S, Martin L, Le Saux O
Int J Mol Sci. 2021; 22(9).
PMID: 33925341
PMC: 8123679.
DOI: 10.3390/ijms22094555.
HPV-Specific Systemic Antibody Responses and Memory B Cells are Independently Maintained up to 6 Years and in a Vaccine-Specific Manner Following Immunization with Cervarix and Gardasil in Adolescent and Young Adult Women in Vaccination Programs in....
Nicoli F, Mantelli B, Gallerani E, Telatin V, Bonazzi I, Marconi P
Vaccines (Basel). 2020; 8(1).
PMID: 31947611
PMC: 7175219.
DOI: 10.3390/vaccines8010026.
Rationalizing the HPV vaccination schedule: A long road to a worthwhile destination.
Brotherton J
Papillomavirus Res. 2019; 8:100190.
PMID: 31759174
PMC: 6889720.
DOI: 10.1016/j.pvr.2019.100190.
Correlates of Human Papillomavirus Vaccination and Association with HPV-16 and HPV-18 DNA Detection in Young Women.
Feder M, Kulasingam S, Kiviat N, Mao C, Nelson E, Winer R
J Womens Health (Larchmt). 2019; 28(10):1428-1435.
PMID: 31264912
PMC: 6797070.
DOI: 10.1089/jwh.2018.7340.
A prospective, single-arm, open-label, non-randomized, phase IIa trial of a nonavalent prophylactic HPV vaccine to assess immunogenicity of a prime and deferred-booster dosing schedule among 9-11 year-old girls and boys - clinical protocol.
Zeng Y, Moscicki A, Sahasrabuddhe V, Garcia F, Woo H, Hsu C
BMC Cancer. 2019; 19(1):290.
PMID: 30935375
PMC: 6444524.
DOI: 10.1186/s12885-019-5444-4.
Cellular Immune Responses 6 Years Following 1, 2, or 3 Doses of Quadrivalent HPV Vaccine in Fijian Girls and Subsequent Responses to a Dose of Bivalent HPV Vaccine.
Toh Z, Cheow K, Russell F, Hoe E, Reyburn R, Fong J
Open Forum Infect Dis. 2018; 5(7):ofy147.
PMID: 30019002
PMC: 6041981.
DOI: 10.1093/ofid/ofy147.
Persistence of memory B-cell and T-cell responses to the quadrivalent HPV vaccine in HIV-infected children.
Weinberg A, Huang S, Moscicki A, Saah A, Levin M
AIDS. 2018; 32(7):851-860.
PMID: 29424778
PMC: 5869173.
DOI: 10.1097/QAD.0000000000001773.
Analysis of Memory B-Cell Responses Reveals Suboptimal Dosing Schedule of a Licensed Vaccine.
Scherer E, Smith R, Carter J, Wipf G, Gallego D, Stern M
J Infect Dis. 2017; 217(4):572-580.
PMID: 29186468
PMC: 5853470.
DOI: 10.1093/infdis/jix566.
Cellular immune responses of older adults to four influenza vaccines: Results of a randomized, controlled comparison.
Kumar A, McElhaney J, Walrond L, Cyr T, Merani S, Kollmann T
Hum Vaccin Immunother. 2017; 13(9):2048-2057.
PMID: 28635557
PMC: 5612046.
DOI: 10.1080/21645515.2017.1337615.
Risk of Delayed Human Papillomavirus Vaccination in Inner-City Adolescent Women.
Schlecht N, Diaz A, Shankar V, Szporn A, Wu M, Nucci-Sack A
J Infect Dis. 2016; 214(12):1952-1960.
PMID: 27738056
PMC: 5142096.
DOI: 10.1093/infdis/jiw486.
An exploration of individual- and population-level impact of the 2-dose HPV vaccination schedule in pre-adolescent girls.
Donken R, Bogaards J, van der Klis F, Meijer C, de Melker H
Hum Vaccin Immunother. 2016; 12(6):1381-93.
PMID: 27171128
PMC: 4964747.
DOI: 10.1080/21645515.2016.1160978.
Less than 3 doses of the HPV vaccine - Review of efficacy against virological and disease end points.
Basu P, Bhatla N, Ngoma T, Sankaranarayanan R
Hum Vaccin Immunother. 2016; 12(6):1394-402.
PMID: 26933961
PMC: 4964672.
DOI: 10.1080/21645515.2016.1146429.
Randomized Open Trial Comparing 2-Dose Regimens of the Human Papillomavirus 16/18 AS04-Adjuvanted Vaccine in Girls Aged 9-14 Years Versus a 3-Dose Regimen in Women Aged 15-25 Years.
Puthanakit T, Huang L, Chiu C, Tang R, Schwarz T, Esposito S
J Infect Dis. 2016; 214(4):525-36.
PMID: 26908726
PMC: 4957434.
DOI: 10.1093/infdis/jiw036.